© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 14, 1039,
July 16, 2003
© 2003 Oxford University Press
NEWS |
Awards, Appointments, Announcements
Five cancer researchers received the General Motors Cancer Research Foundation Awards, a $250,000 prize presented in Washington, D.C., in June. Ronald M. Evans, Ph.D., a professor at the Salk Institute for Biological Studies in La Jolla, Calif., and Pierre Chambon, M.D., emeritus director of the Institute of Genetics and of Molecular and Cellular Biology at the Louis Pasteur University in France, were awarded the Alfred P. Sloan Jr. Prize for their contributions to the understanding of steroid and nuclear hormone receptors.
V. Craig Jordan, Ph.D., director of the Lynn Sage Breast Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, was awarded the Charles F. Kettering Prize for pioneering the practical use of anti-estrogens, particularly tamoxifen, as targeted therapy for the treatment and prevention of breast cancer.
Yuan Chang, M.D., Ph.D., and Patrick S. Moore, M.D., both professors at the University of Pittsburgh Cancer Institute, were awarded the Charles S. Mott Prize for their discovery and characterization of the causative agent of Kaposi’s sarcoma.
Alex Markham, Ph.D., has been appointed chief executive of Cancer Research U.K. Markham, director of Leeds University’s molecular medicines unit and an honorary consultant at the Leeds Teaching Hospital NHS Trust, takes the position in September. He succeeds Paul Nurse, Ph.D., who will become president of Rockefeller University in New York.
David A. Kessler, M.D., former commissioner of the U.S. Food and Drug Administration and dean of the Yale University School of Medicine, New Haven, Conn., has been named dean of the University of California San Francisco School of Medicine. He will begin his new position on Sept. 1, 2003.
Barry Goldspiel, PharmD, program director of the Specialized Residency in Oncology Pharmacy Practice at the National Institutes of Health, was awarded the U.S. Public Health Service George F. Archambault Career Achievement in Pharmacy Award for his contributions to improving cancer patient care and oncology pharmacy practice.
William T. McGivney, Ph.D., chief executive officer of the National Comprehensive Cancer Network, received the National Humanitarian Health Care Award from the Patient Advocate Foundation for his leadership in improving patient access to quality health care.
John Surprenant has been named executive director of the Anne Arundel Medical Center’s new DeCesaris Cancer Institute. Surprenant was previously administrator of the St. John Health Oncology program in Detroit, Mich.
Peter R. Reczek, Ph.D., has been appointed director of technology transfer at the Roswell Park Cancer Institute in Buffalo, New York. Reczek is an assistant professor in the department of molecular and cellular biophysics at Roswell Park Cancer Institute.
James L. Mohler, M.D., has been named chair of the department of urologic oncology at Roswell Park Cancer Institute. Mohler was previously director of the Prostate Cancer Research Program at the University of North Carolina, Lineberger Comprehensive Cancer Center in Chapel Hill.
The Kirk A. & Dorothy P. Landon Foundation and the American Association for Cancer Research are accepting nominations for the 2004 Landon-AACR Prizes, which recognize important discoveries in basic and translational cancer research. The deadline for nominations is Friday, Aug. 8. More information is available at http://www.aacr.org/1619.asp.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||